Advertisement

Volume 132, Issue 14

 

 

October 4, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Special report: defining monoclonal gammopathy of clinical significance. See the article by Fermand et al.

Erythroferrone inhibits the induction of hepcidin by BMP6
In this Plenary Paper, Arezes et al elucidate the mechanism of hepcidin inhibition by erythropoietin (EPO). They demonstrate that EPO induces erythroferrone, which in turn binds to BMP proteins, blocking BMP-induced hepcidin secretion.


Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
In a Special Report, Fermand and colleagues introduce the concept of monoclonal gammopathy of clinical significance, in which seemingly trivial monoclonal proteins cause clinically significant organ damage that may be responsive to appropriate cytotoxic therapies.


An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
Morschhauser et al demonstrate efficacy and safety of the second-generation anti-CD20 antibody obinutuzumab in combination with lenalidomide in relapsed/refractory follicular lymphoma.


Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Scarfò et al present preclinical studies supporting the use of CD37 as a target antigen for novel chimeric antigen receptor T-cell reagents. They demonstrate activity against B- and T-cell lymphomas both by single-antigen targeting and by dual-specific therapy in combination with anti-CD19.


CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Neither the therapeutic efficacy nor the toxicity of thalidomide and its derivatives is recapitulated in mouse models. Fink and colleagues establish that this can be attributed to a single base difference between mouse and human cereblon, as a mutant CrbnI391V induces drug sensitivity and fetal loss.


Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Nodular lymphocyte-predominant Hodgkin lymphoma (HL) is a rare, indolent form of HL; however, patients can have late relapses. Eichenauer et al report on the excellent prognosis of relapsed disease in this subtype of HL.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.